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Abstract
Background: Antibiotic resistance (ABR) poses a major threat to health and economic wellbeing worldwide.
Reducing ABR will require government interventions to incentivise antibiotic development, prudent antibiotic use,
infection control and deployment of partial substitutes such as rapid diagnostics and vaccines. The scale of such
interventions needs to be calibrated to accurate and comprehensive estimates of the economic cost of ABR.
Methods: A conceptual framework for estimating costs attributable to ABR was developed based on previous
literature highlighting methodological shortcomings in the field and additional deductive epidemiological and
economic reasoning. The framework was supplemented by a rapid methodological review.
Results: The review identified 110 articles quantifying ABR costs. Most were based in high-income countries only
(91/110), set in hospitals (95/110), used a healthcare provider or payer perspective (97/110), and used matched
cohort approaches to compare costs of patients with antibiotic-resistant infections and antibiotic-susceptible
infections (or no infection) (87/110). Better use of methods to correct biases and confounding when making this
comparison is needed. Findings also need to be extended beyond their limitations in (1) time (projecting present
costs into the future), (2) perspective (from the healthcare sector to entire societies and economies), (3) scope (from
individuals to communities and ecosystems), and (4) space (from single sites to countries and the world). Analyses
of the impact of interventions need to be extended to examine the impact of the intervention on ABR, rather than
considering ABR as an exogeneous factor.
Conclusions: Quantifying the economic cost of resistance will require greater rigour and innovation in the use of
existing methods to design studies that accurately collect relevant outcomes and further research into new
techniques for capturing broader economic outcomes.
Keywords: Antimicrobial resistance, Antibiotics, Economic costs, Economic evaluation
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: mark.jit@lshtm.ac.uk
1The National Institute for Health Research (NIHR) Health Protection Research
Unit in Immunisation, London School of Hygiene & Tropical Medicine,
Keppel Street, London WC1E 7HT, UK
2Modelling and Economics Unit, National Infections Service, Public Health
England, London, UK
Full list of author information is available at the end of the article
Jit et al. BMC Medicine           (2020) 18:38 
https://doi.org/10.1186/s12916-020-1507-2
Background
For several decades now, it has been known that antibiotic
resistance (ABR) among human pathogens is detrimental
to health and economic wellbeing [1–3]. International rec-
ognition of its threat to modern medicine and society has
increased in recent years [4–7]. Several national and inter-
national working groups have proposed actions to mitigate
its further development, with recommendations including
novel funding structures for new antibiotic research and
development, development and use of technologies like
diagnostics and vaccines that may reduce the need for anti-
biotics, education to enhance antibiotic stewardship as well
as better infection control practices such as ensuring uni-
versal access to sanitation, hygiene and safe water [4–7].
Many of the societal conditions that have increased
the threat of ABR, such as a lack of investment in anti-
biotic development and antibiotic overuse, stem from
market failure, i.e. the private interests of individuals
conflicting with the public interests of society. When
used appropriately to treat bacterial infections, antibi-
otics generate private (individual) benefits by expediting
infection clearance and recovery from associated illness,
whilst also generating public benefits by reducing the
spread of infection across the rest of the population
(positive externalities). However, these public benefits
are usually outweighed by the costs that fall on others
who do not use them (negative externalities) — their use
can select for bacteria with more resistance, hence erod-
ing the effectiveness of future antibiotic use. In other
words, using antibiotics consumes the global stock of
antibiotic effectiveness, making antibiotics less beneficial
to everyone who uses them. Additionally, antibiotics
confer no benefits against viral infections (and indeed
bacterial infections that are resistant to that antibiotic).
Since there is usually uncertainty about the aetiology
and susceptibility of an infection, patients may demand
antibiotic prescriptions and their prescribers are often
incentivised to respond to this demand whether it be for
a bacterial or viral infection.
Because self-interested antibiotic consumers have little
motivation to conserve the global stock of antibiotic
effectiveness, most of the recommended interventions to
combat ABR are unlikely to succeed without government
intervention at the national and international levels. In-
deed, even when prescribers act as custodians for antibiotic
consumption, they are predicted to prescribe antibiotics to
patients even when they only have a small chance of
benefit [8].
To correct these market failures and align individual and
societal interests, governments (and other healthcare fun-
ders such as donors and private insurers) may incentivise
prudent antibiotic use through taxes, subsidies and regula-
tions, and fund research in antibiotics and other technolo-
gies [9]. However, the scale of these interventions needs to
be calibrated to the size of the negative externality, such
that it reflects the social value of prolonging antibiotic
effectiveness. Striking this balance requires an accurate
understanding of the economic cost of ABR [10].
Several reviews have examined the cost of ABR. In
particular, five reviews covering the periods 1995–2009
[11], 1987–2000 [12], 2000–2012 [13], 2013–2015 [14]
and 2000–2016 [15] found 36, 21, 24, 11 and 8 studies,
respectively, assessing the cost of ABR and/or the cost-
effectiveness of related interventions. The reviews
highlighted methodological shortcomings and biases in
the literature as well as challenges in extrapolating study
findings to a societal scale and to the long term. In par-
ticular, the heterogeneity in methods and quantitative
results across different studies complicates meaningful
comparisons [11, 14, 16, 17]; this heterogeneity is
present even when restricting comparisons to studies of
a particular organism within the hospital setting [18].
Despite these issues in interpreting and quantifying
the costs of ABR, none of the reviews provided detailed
proposals of how the evidence gaps and study heteroge-
neities could be addressed in future studies. Indeed, a
lack of certainty on the current and potential future eco-
nomic burden of ABR, especially in low- and middle-
income countries, has been recognised to have hindered
international action [4].
Several estimates have recently been made of the global
ABR burden to present the case for investing in measures to
combat ABR [7, 19, 20]. These global estimates were per-
formed largely independently of the hospital-based litera-
ture, relying instead on international surveillance databases
that have been noted to suffer from representativeness
issues, confounding and biasedness around attributable
mortality and ABR prevalence as well as contestable costing
assumptions [21]. Furthermore, quantifying the economic
burden of ABR on its own is of little value for decision-
making unless it can inform estimates of the impact that
different interventions can have on this burden.
To overcome these evidence gaps, we present a concep-
tual framework that can act as a roadmap for future stud-
ies to describe how they can reduce bias and be extended
in time, perspective, scope and space. We use this frame-
work to develop comprehensive recommendations for the
design of future studies that will allow policy decisions
based on a clearer and more consistent methodology as
well as on more comprehensive evidence. Our framework
is supplemented by a rapid methodological review of
studies that consolidates articles in previous reviews on
ABR costs and the impact of ABR-related interventions.
Methods
Conceptual framework
Previous reviews [11–15] have highlighted methodo-
logical shortcomings in the ABR cost literature, including
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heterogeneity in methodological choices [11, 14, 15], biases
in study design and analysis [11, 14], lack of evidence outside
high-income [12, 15] and hospital [12, 13] settings, and fail-
ure to consider the future consequences of ABR [13]. We
used these critiques to develop a conceptual framework of
how current studies could be strengthened and extended to
address these shortcomings. This was supplemented by add-
itional deductive epidemiological and economic reasoning.
The deductive reasoning was guided by the literature on
causal inference [14, 22–26], perspective and scope of eco-
nomic impact [27], and opportunity costs [28]. We then con-
ducted a rapid methodological review to (1) extract broad
features of ABR cost studies relevant to the methods they
use, (2) survey the methods used to cost ABR and (3) exam-
ine the extent to which these methods addressed methodo-
logical shortcomings. A narrative synthesis of these methods
and their limitations was developed and then used to further
modify our conceptual framework.
Rapid methodological review
To inform the conceptual framework, we conducted a
rapid methodological review of published and grey litera-
ture. For published literature, we searched PubMed and
Ovid MEDLINE for all studies up to November 4th, 2019
(see Additional file 1 for search terms). For grey literature,
the websites for the World Bank (www.worldbank.org),
the European Centre for Disease Prevention and Control
(www.ecdc.europa.eu), and the Centre for Infectious
Disease Research and Policy (www.cidrap.umn.edu) were
examined. We also reviewed the reference lists of five
related reviews [11–15]. Studies were not screened in
duplicate.
We included all English-language articles (including con-
ference abstracts in peer-reviewed journals) that quantified
the cost of ABR from any economic perspective, including
papers that quantified these costs as part of an economic
evaluation of an intervention to reduce ABR. Both primary
data and secondary data analyses were included as long as
real costs were an outcome. We included studies that
calculated the incremental costs of treating patients with
resistant infections relative to either treating patients with a
susceptible infection or no infection at all.
Exclusion criteria were (1) studies about ABR in Myco-
bacterium tuberculosis alone (due to the large volume of
this literature using techniques relevant to tuberculosis
alone) or non-bacterial pathogens only; (2) studies about
bacteria in non-human species alone; (3) reviews, com-
mentaries or theoretical papers that did not estimate a
cost associated with ABR that is applicable in a real-
world setting; (4) studies that calculated the cost of an
intervention (e.g. use of an antibiotic) in the presence or
absence of ABR rather than the actual cost of ABR; (5)
studies that calculated the cost in terms of total anti-
biotic use and/or prescription expenditure alone rather
the cost associated with a resistant infection; and (6)
studies that were not accessible to the authors.
Articles that discussed approaches to quantify costs
but did not present numerical results were also exam-
ined to inform the wider discussion.
The data extracted from each study is shown in
Additional file 2. Descriptive summary statistics were cal-
culated on publication date, country, healthcare setting,
economic perspective, bacterial species and study design.
Full text papers were read for details on study design and
recommendations. A reporting checklist of the review
methodology is shown in Additional file 3.
Results of rapid methodological review
Descriptive results
We found 6347 articles from combining the database
search and references from previous reviews. Of these,
110 articles were included following abstract and full-
text review (Fig. 1; details in Additional file 2), including
43 articles that had not been included in any previous
review.
The articles were published during 1998–2019, with
half (55/110) being published since 2011. Most (91/110)
presented results for high-income countries only, with
almost half (48/110) from the United States. Only 12
were from low- and middle-income countries (Brazil,
China, Columbia, Ethiopia, India, Senegal, Thailand and
Turkey), while 7 included multi-country results. Most
(95/110) were set in hospitals (8 in intensive care units),
with the remainder being from community care (either
acute or long-term) or mixed settings. Most (97/110)
used a healthcare provider or payer perspective, with the
remainder using either a societal perspective (8/110) or
multiple perspectives (5/110). The most common (87/
110) method for costing was using pairwise matching or
regression on a patient cohort, while the remaining stud-
ies used a cohort exclusively of patients with resistant
infections (1/110), ecological analysis or meta-regression
of multiple studies (4/110), or mathematical modelling
(18/110) to estimate costs.
Around half (52/110) examined Gram-positive bacteria
alone, with Staphylococcus aureus, Enterococci and Strepto-
coccus pneumoniae being the most common. Fewer (29/
110) examined Gram-negative bacteria alone, with Entero-
bacteriaceae, Pseudomonas aeruginosa and Acinetobacter
baumannii being the most common. The remainder looked
at mixed groups of patients with both Gram-positive and
Gram-negative bacteria.
Hospital-based studies
Similar to previous reviews [12–15, 22], we found that
most studies focused solely on treatment costs incurred
by hospital patients with antibiotic-resistant infections,
using one of two designs:
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 A matched cohort design, where patients with
antibiotic-resistant and antibiotic-susceptible
infections (or no infection at all) are matched and
their cost outcomes compared. Matching is based
on patient characteristics and differs widely across
studies; some have matched only on patient age and
gender, while others have used diagnostic codes,
severity-of-illness scores or length of stay from
admission to infection onset. However, such studies
rarely explore whether the matching characteristics
are good indicators of the risk of acquiring an
antibiotic-resistant infection [22].
 Regression on a patient cohort to link the presence
of an antibiotic-resistant infection with cost-related
explanatory variables. In both cases, the outcome
variable is treatment costs (calculated using hospital
charges and/or standard reimbursement tariffs) or
an intermediate outcome such as length of stay,
which is then used to calculate costs. The latter
approach may underestimate costs by ignoring other
cost elements that may be greater for antibiotic-
resistant infections such as testing and prescription
costs, management of complications, and isolation
ward and intensive care stays [18].
Many studies suffer from methodological shortcomings
that may either underestimate or overestimate of the actual
cost of ABR, as has been pointed out previously [14, 17, 23].
These shortcomings include (1) unmeasured baseline con-
founding (not adjusting for differences in the characteristics
Fig. 1 PRISMA flow diagram showing the review process
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of patients with antibiotic-resistant, antibiotic-susceptible or
no infection that affect their clinical outcomes or treatment
costs), (2) time-dependent confounding (patients with
antibiotic-resistant, antibiotic-susceptible or no infections
have different changes to their characteristics such as health
between the time of admission and acquiring an infection)
[24, 25], (3) time-dependent bias (patients with longer stays
being more likely to acquire antibiotic-resistant infections)
[25], and (4) model misspecification (use of inappropriate
models to relate variables to outcomes, such as the use of
Cox regression models even though the proportional haz-
ards assumption is rarely valid for cost outcomes) [26].
The literature in this area has shown methodological
improvements over time, with greater use of techniques
that can correct for time-dependent biases, such as sur-
vival models incorporating infection as a time-dependent
predictor and multi-state models [29]. However, few stud-
ies adjust for potential time-varying confounding when
focusing on hospital-acquired cases, using g-methods such
as marginal structural models with inverse probability
weighting [25] or nested g-formulae [24]. In contrast to
standard regression methods and multistate models, g-
methods can provide unbiased estimates of an exposure if
there is time-varying confounding that is also affected by
the exposure, provided that confounding is accurately
measured.
The use of regression and propensity score matching
rather than paired cohorts has also increased, which
should reduce residual confounding since paired cohorts
can only control for a limited selection of variables. Instru-
mental variable approaches may offer a more powerful
approach to correct for observable and unobservable con-
founders [22]. However, none of the reviewed studies used
suitable instruments. It may be possible to use rapid policy
shifts, such as changes to hospital cleaning regimens, as in-
struments, but these shifts would need to be sufficiently
large and may be confounded by other time trends.
Conceptual framework
A major limitation of hospital-based studies is that, on
their own, they are insufficient to fully capture ABR eco-
nomic burden on a national or global level or to assess
the impact of interventions against the development of
ABR. The conceptual framework proposed describes
how they can be extended in time, perspective, scope
and space (Fig. 2).
Extension in time: from the present to the long term
Based on present trends, the prevalence of ABR, and
especially multi-drug resistance, is expected to rise
[30–32]. However, most estimates of current ABR eco-
nomic burden do not project estimates into the future,
and hence fail to adequately capture the value of inter-
ventions that may avert catastrophic future scenarios.
A few studies have taken scenario-based approaches
by (1) assuming that future ABR prevalence and/or dis-
ease prevalence will increase by arbitrary amounts sim-
ply to explore what the consequences of such scenarios
would be [7, 19, 20], (2) assuming that all currently sus-
ceptible bacterial strains will acquire ABR in the future
[33], or (3) linearly projecting past data on disease inci-
dence and ABR prevalence [31, 32].
Even the most extreme scenarios may not represent
the worst case, because these projections do not account
for new resistances that bacteria may acquire, including
resistance to current last-resort antibiotics. If this hap-
pens, then the cost of developing new antibiotics or anti-
biotic classes needs to be incorporated. Otherwise, some
analysts have speculated that hospital procedures, such
as organ transplantation and cancer chemotherapy, will
become risky to perform because of untreatable infec-
tions. Approaches to costing such scenarios have been
discussed [16, 19, 34], but no study has presented quan-
titative results of such calculations.
Extension in perspective: from the healthcare payer to society
Most hospital-based studies only consider ABR costs
from the perspective of the healthcare provider (e.g. the
hospital providing treatment). Other perspectives are ar-
guably relevant to decision-makers considering whether
to fund investments with national and global implica-
tions such as developing a new antibiotic.
One such perspective is that of the patient’s house-
hold. If ABR results in longer hospital stays and more
complex procedures, then this may increase household
out-of-pocket costs such as co-payments for treatment,
transport costs, caregiver accommodation costs and
childcare costs. Patients and caregivers may miss work
and lose income. These costs may be especially large (in
comparison to existing income or wealth) for poorer
patients, especially those in countries without universal
health coverage [35]; none of the reviewed papers con-
sidered these distributional perspectives. Such distribu-
tional concerns should also be considered in the use of
interventions to correct for market failures in antibiotic
use. For instance, taxing antibiotics may particularly bur-
den the poor since the demand for antibiotics is relatively
income inelastic [36]; therefore, compensatory measures
may be appropriate such as funding healthcare services
and improvements in infection prevention strategies that
will reduce the overall need for antibiotics [10].
A further dimension of household economic burden is
the value of avoiding pain, suffering and worry to pa-
tients and caregivers, including the value of avoiding
premature mortality. In economic evaluations, this is
usually done by either (1) monetising this value by elicit-
ing people’s willingness to pay to avoid morbidity and
mortality or (2) valuing it using a separate metric such
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as quality- or disability-adjusted life years. As an ex-
ample, Phelps [37] costed each avoided death as having
a value of US$1 m (2 m in 2017 I$). Capturing household
and psychosocial aspects of ABR burden is especially
important in low- and middle-income settings where
treatment costs and hospitalisation rates may be lower
(due to low labour costs and poor healthcare access, re-
spectively), but the human cost of ABR remains high.
The societal perspective is the broadest and includes
the effect that morbidity and mortality have on eco-
nomic production. Only 8/110 of the reviewed studies
included explicitly mentioned incorporating productivity
costs; those that did, concluded that productivity costs
were greater than direct medical costs. Most (6/110)
used the human capital method, whereby any time lost
from work as a result of death, sickness or caregiving is
converted into production costs by multiplying either by
the average wage or by the national GDP per capita; none
subtracted future medical or non-medical consumption as
recommended by some economists [38]. Two studies argue
that the human capital method underestimates the impact
of ABR to society because it ignores the broader macroeco-
nomic impact of reduced labour supply, increased health-
care demand and reduced consumption due to sickness,
disability, premature mortality and fear of infection. In-
creased rates of ABR are likely to have a detrimental effect
on unemployment, inflation, total factor productivity and,
ultimately, national income [9]. There are a number of ways
through which studies have tried to incorporate these
macroeconomic effects — capturing labour and capital
stocks with the Cobb–Douglas function [19], modelling
intersectoral flows with Social Accounting Matrix methods
[19, 20] and dynamically capturing economic shocks with
Computable General Equilibrium methods [9, 39].
Fig. 2 Conceptual framework outlining options discussed in the text to extend the scope of studies estimating the costs of antibiotic resistance
(see text for references)
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Additionally, when taking the societal perspective, dis-
ease not resulting in hospitalisation (i.e. treated in the
community, in primary care or in outpatient clinics)
becomes important because this may still result in
productivity losses even if direct healthcare costs
are low.
Extension in scope: from the individual patient to the
community
Most studies have considered only the difference in costs of
treating patients with antibiotic-susceptible and antibiotic-
resistant infections; however, ABR can also increase costs
for patients without antibiotic-resistant infections. For
instance, patients with infections for which ABR is wide-
spread are routinely given costly ABR tests and/or empiric-
ally prescribed antibiotics that are costlier and have worse
side effects than first-line antibiotics. One study found that
ABR contributed to a 22% increase in per prescription
antibiotic spending on otitis media [40].
Some antibiotics are given prophylactically to patients
particularly susceptible to infections such as pregnant
women [41] and cancer or surgical patients [34, 42]; loss
of antibiotic effectiveness will decrease prophylaxis
effectiveness and worsen patient outcomes [34]. These
effects can be translated into costs [16], although no
paper we reviewed has done this explicitly.
By considering only the incremental cost of treating
antibiotic-resistant infections compared to antibiotic-
susceptible infections, most studies imply that, even if
ABR was eliminated, patients would still be infected by a
susceptible infection. However, bacterial transmission is
often driven by the ineffectiveness or slow effectiveness
of antibiotic treatment, causing antibiotic-susceptible
strains to spread more slowly; thus, reducing ABR may
also reduce overall infection incidence.
Further spill-overs occur from the opportunity costs
associated with antibiotic resistance to others in the
community who may be unable to access timely
healthcare when resources, such as hospital beds, are
blocked by patients with longer stays due to resistant
infections. These opportunity costs can be expressed
in terms of monetary time costs or in terms of
impact on hospital revenues [43] or the health of
other patients [28].
Finally, resistant infections arise and are transmitted
within and between humans, non-human animals and
the environment. Patients with resistant infections can
move between different healthcare sectors such as
hospitals, intermediate/long-term care and the com-
munity. These effects can influence the impact of
interventions; the methods to capture them are de-
scribed in more detail in the section on “The impact
of interventions” below.
Extension in space: from one hospital to national/global
estimates
Antibiotic-resistant organisms cross boundaries between
host species (humans and other animals), hospitals and
countries. Single hospital studies may be useful to estimate
the cost of a localised outbreak, but the impact of policy
instruments usually needs to be considered at the national
or even global level. Game-theoretic analyses suggest that
optimal antibiotic allocation requires cooperation between
countries rather than allowing individual patients or even
countries to act in their own self-interest [44].
Only 18/110 of the reviewed studies (of which only 7
were published before 2018) and a further 4 studies
found in the grey literature extrapolated findings from
study sites to countries or multi-country groupings
(Table 1). The most common approach is to multiply in-
cremental costs in study sites by the total number of
antibiotic-resistant cases across the entire geography.
The shortcoming of this approach is that data from a
single hospital or even several hospitals often lack exter-
nal validity [32]. Quantitative comparisons of the litera-
ture have found substantial differences in costs between
studies [11, 17, 22]. Another approach is to synthesise
information from multiple studies as was done in cross-
European analyses [6]. Since studies are heterogeneous,
in the long term, multi-centre studies with a common
methodology may improve both statistical power and
validity beyond study settings [22].
A separate approach has been to rely on national [48,
52, 53, 55] or global [19, 20] surveillance databases
rather than individual sites. This offers greater external
validity but may only be accurate in countries with
representative patient data on healthcare utilisation, pre-
scribing and antibiotic susceptibility, ideally linked to ac-
count for dependencies in these variables. The validity of
global antibiotic use databases has been questioned, particu-
larly in resource-poor settings, given the difficulty of captur-
ing antibiotic supply from informal providers [58, 59].
Furthermore, cultures are less frequently taken in resource-
poor settings and often only when patients do not seem to
respond to empirical antibiotic therapy, leading to inflated es-
timates of ABR prevalence [59]. A better approach may be to
estimate ABR costs using large prospective population-based
or multi-centre studies where antibiotic susceptibility is
tested in all patients seeking healthcare for acute infections.
When patient-level data are not available, studies have
related ABR with costs on an ecological level (by subna-
tional region [60, 61] or country [35]). The usual ap-
proach is to linearly regress the proportion of isolates
that are resistant with healthcare expenditure (alongside
other explanatory variables) [35, 60]. In some cases, an
intermediate outcome, such as overall pathogen preva-
lence [61], is the primary outcome variable, which is
then converted into costs.
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Table 1 Estimates of national, multinational and global costs of antibiotic resistance. Costs were inflated using local GDP deflators
and converted to 2018 international dollars (I$) using purchasing power parities, both from data published by the World Bank and
OECD
Study Geography Pathogens Costs in original currency Costs in 2018 I$ Costs considered
Studies in the grey literature
ECDC and EMEA [6] EU,
Iceland,
Norway
S. aureus, Enterococcus
spp., S. pneumoniae, E.
coli, Klebsiella spp., P.
aeruginosa
1.5 bn/year EUR (2007) 2.1 bn/year Increased treatment costs, reduced
productivity and labour supply due
to morbidity and premature
mortality
KPMG [19] EU,
Iceland,
Norway
Global
E. coli, K. pneumoniae,
S. aureus, HIV, TB, malaria
1.6 bn/year EUR (2012)
1.66–6.08% of global
GDP in 2050
2.3 bn/year Increased treatment costs, reduced
productivity and labour supply due
to morbidity and premature
mortality
RAND Europe [20] Global E. coli, K. pneumoniae,
S. aureus, HIV, TB, malaria
0.5–6.0 tn USD (2011)
per year in 40 years
(0.14–1.9% of global
GDP)
0.6–6.8 tn per year
in 40 years
Reduced labour supply and
productivity due to increased
morbidity, mortality and caregiving
Reduced inter-sectoral transactions
and trade
World Bank [7] Global Any 1.0–3.4 tn USD (2017)
per year in 2030
(1.1–3.8% of global
GDP)
1.0–3.5 tn I$ per
year in 2030
Reduced labour supply due to
premature mortality
Studies in the rapid review
of published literature
Chen et al. [45] Ethiopia S. pneumoniae 15.8 m/year USD (2017) 16.2 m/year Increased treatment costs and
productivity losses due to morbidity
and premature mortality
Chesson et al. [46] USA N. gonorrhoeae 378m/year USD (2016) 395 m/year Increased treatment costs
de Kraker et al. [32] 31
European
countries
Bloodstream infections
caused by MRSA
and G3CREC
62 m/year EUR (2007) 87 m/year Increased length of hospital stay
Elbasha [47] USA Any 0.4–19 bn/year USD
(1996)
0.6–29 bn/year “Deadweight loss”: reduced
antibiotic effectiveness leading to
poorer treatment outcomes due to
overprescribing antibiotics
Johnston et al. [48] United
States
Multi-drug resistant
organism
2.39–3.38 bn/year USD
(2017)
2.45–3.46 bn/year Increased treatment costs
Lee et al. [49] USA Community-associated
MRSA
Healthcare: 478 m/year
USD (2011)
Society: 2.2 bn/year
USD (2011)
Healthcare: 539 m/
year
Society: 2.5 bn/year
Increased treatment costs and
productivity loss due to morbidity
and premature mortality
Michaelidis et al. [50] USA Any 4.4 bn/year USD (2013) 4.8 bn/year Cost of antibiotic use and
stewardship
Naylor et al. [29] England E. coli Third-generation
cephalosporin:
366,600/year GBP
(2012) Piperacillin/
tazobactam: 275,4000/
year GBP (2012)
Third-generation
cephalosporin: 578,
000/year
Piperacillin/
tazobactam: 434,000
Increased treatment costs
Phelps [37] USA Any 0.15–3 bn/year
USD (1984)
0.3–6.3 bn/year Treatment costs, mortality
Phodha et al. [51] Thailand Nosocomial infections
due to five bacterial
species
Healthcare: 2.3 bn/year
USD (2012)
Society: 4.2 bn/year
USD (2012)
Healthcare: 2.5 bn/
year
Society: 4.6 bn/year
Increased treatment costs
Increased societal costs
(components not
reported)
Shrestha et al. [52] USA and
Thailand
Any USA: 2.9 bn/year
USD (2016)
Thailand: 0.5 bn/year
USD (2016)
USA: 3.0 bn/year
Thailand:0.5 bn/year
Increased treatment costs and
productivity loss due to
morbidity and premature mortality
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The impact of interventions
While most studies have focused on the overall ABR
economic burden, some have examined the impact and
cost-effectiveness of interventions that could potentially
affect ABR. Most of these consider ABR alone as an exo-
geneous factor affecting the cost-effectiveness of an inter-
vention but not itself influenced by the intervention. For
instance, many cost-effectiveness evaluations of antibiotics
have incorporated the effect of ABR on the effectiveness
of antibiotic treatment [62] or the types of antibiotics that
can be used [63]. Similarly, cost-effectiveness studies of
interventions to reduce antibiotic consumption (such as
stewardship programmes and rapid diagnostic tests) have
typically considered intervention impact on antibiotic
volume and costs. However, few studies have considered
the potential impact of antibiotic consumption on (1)
reducing ABR by preventing onward transmission of a
bacteria susceptible to the antibiotic (positive externality)
and/or (2) inducing ABR by increasing selective pressure
(negative externality).
Some studies have captured these externalities using de-
scriptive statistical approaches such as (1) using empirical
data to evaluate the impact of a discrete intervention affect-
ing antibiotic consumption (such as introduction of a stew-
ardship programme) on ABR prevalence or treatment cost
[64]; (2) estimating a fixed ratio between antibiotic con-
sumption and ABR costs (or an intermediate proxy such as
ABR prevalence or hospital bed-days used to treat infection
with a particular pathogen) [54]; or (3) fitting a
statistical model, such as linear correlation between
antibiotic consumption and ABR costs (or an
intermediate proxy), using data sampled over several
countries and/or years [52].
These methods require an estimate of ABR costs. In
hospital studies, this can be estimated as the cost of
treating resistant infections in the hospital [64]. In eco-
logical studies, ABR costs are often regarded as the cost
of all antibiotics consumed in a single country and year
[50, 65]. The most sophisticated methods derive from
work by Phelps [37], who explicitly modelled market
dynamics between antibiotic producers and consumers
as well as the relationship between antibiotic consump-
tion and the emergence of ABR. This was then used to
estimate the total negative externality of annual anti-
biotic use in the USA, defined as the welfare loss due to
ABR minus the welfare benefits that come from using
antibiotics. This model was independently extended by
Elbasha [47] and Kaier [66–68].
All the above methods make major simplifying
assumptions, as described below:
 Some models assume that resistance against a
particular antibiotic is only affected by the use of
antibiotics of the same class. In practice, antibiotic
use can affect ABR against an antibiotic of a
different class. For instance, amoxicillin, which is
typically prescribed for respiratory tract infections, is
associated with increased trimethoprim and
ciprofloxacin resistance in Escherichia coli causing
urinary tract infections [69, 70]. Conversely, higher
nitrofurantoin use was found to be associated with
lower levels of trimethoprim and amoxicillin
Table 1 Estimates of national, multinational and global costs of antibiotic resistance. Costs were inflated using local GDP deflators
and converted to 2018 international dollars (I$) using purchasing power parities, both from data published by the World Bank and
OECD (Continued)
Study Geography Pathogens Costs in original currency Costs in 2018 I$ Costs considered
Smith et al. [39] UK MRSA 0.4–1.6% of national
GDP, equivalent to
3–11 bn GBP (1995)
6.5–24.0 bn Reduced labour supply and
productivity,
leading to less capital investment
and
lowered productivity
Thorpe et al. [53] USA Any 2.2 bn/year USD (2016) 2.3 bn/year I$ Increased treatment costs due to
morbidity
Tillekeratne et al. [54] Sri Lanka Any 229m/year USD (2017) 235 m/year Not specified – costs extrapolated
from US
and Thai studies
Touat et al. [55] France Gram-negative bacteria 287 m/year EUR (2015) 397 m/year Increased treatment costs
US Congress, Office
of Technology
Assessment [56]
USA Nosocomial infections
due to six bacterial
species
1.3 bn/year USD (1992) 2.1 bn/year Hospital treatment costs
Zhen et al. [57] China Intra-abdominal bacterial
infections
Healthcare: 37 bn/year
CNY (2015)
Society: 111 bn/year
CNY (2015)
Healthcare: 12 bn/
year
Society: 35 bn/year
Increased treatment costs,
3x multiplier for
societal costs
bn billion, CNY Chinese Yen, ECDC European Centre for Disease Prevention and Control, EMEA European Medicines Agency, G3CREC third-generation
cephalosporin-resistant E. coli, MRSA methicillin-resistant Staphylococcus aureus, TB tuberculosis, tn trillion, USD US Dollar
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resistance, potentially due to collateral sensitivity or
a negative correlation between resistance genes [69].
 Models relating (human) antibiotic consumption to
ABR assume that the relationship is not confounded
by between-country differences such as in infection
prevention and control measures and agricultural
antibiotics use. Reverse causality could play a role in
cross-sectional data since physicians may avoid a
particular antibiotic if ABR to that antibiotic is
known to be high in that population [71]. In some
cases, the potential role of reverse causality could be
assessed using structural equation models or
instrumental variables.
 Some models assume that the relationship is
instantaneous, i.e. that a given level of antibiotic use
will immediately result in some level of ABR. In
practice, bacteria take time to acquire resistant
genes and reach a new equilibrium prevalence in a
population. Indeed, high levels of ABR may be the
cumulative effect of years of antibiotic use, i.e.
present antibiotic use may be depleting the health
and wellbeing of future generations [72].
Furthermore, future changes in ABR can be
unpredictable. While the emergence of mutations
conferring ABR to certain antibiotics is predictable
to some extent, the timing and impact of the
introduction of new ABR genes into mobile genetic
elements or widespread bacterial strains is not [10, 73].
 Models often assume that the relationship between
antibiotic use and ABR is linear (or can be described
with a simple function); this has some basis in
ecological observations at the national level [74].
However, investigators using non-linear models
suggest that the relationship is more complex and
dynamic [3, 75, 76].
Advanced modelling approaches may circumvent some
but not all of these limitations. Time-series approaches to
modelling the relationship between population antibiotic
use and ABR in hospitals suggest that this relationship is
indeed non-linear [77]. Furthermore, machine learning
approaches, such as boosted regression trees, can also be
used, allowing flexibility in the functional relationship [70].
Dynamic effects, such as time delays and feedback
loops, can be captured with transmission dynamic
models [45, 78], dynamic Bayesian Markov models [79]
or by including lagged covariates into regression ana-
lysis. Transmission dynamic models capture the effect of
interventions on onward transmission and competition
between susceptible and resistant bacterial strains, and
can be used to track changes in ABR prevalence over
time. Transmission dynamic models with strain competi-
tion that incorporate economic outcomes are rare [45, 78,
80]; one reason is that such models require data on
antibiotic use in different settings, acquisition and carriage
(duration) of antibiotic resistant bacteria, environmental
swabs, movement of patients and contact patterns, rates
of infection, and the associated current and future impact
on patient outcomes and costs in order to predict the
impact of interventions on ABR and the associated
costs. However, some of them note that predictions
about optimal policy may differ when economic con-
siderations are incorporated into purely epidemio-
logical/ecological models [3].
A key issue around all models is the reversibility of
ABR, i.e. whether susceptible strains will eventually out-
compete resistant strains when reducing selective pressure
from antibiotic use. Most ABR mechanisms come with fit-
ness costs that reduce the competitiveness of resistant
strains compared to susceptible strains in the absence of
antibiotic exposure [68]. However, reductions in antibiotic
prescribing have not always led to reductions in ABR
prevalence, potentially due to a lack of fitness costs, com-
pensatory mutations that reduce fitness costs, and co-
selection of ABR genes by other antibiotics. The reversibil-
ity of ABR likely depends on the setting, the bacterial spe-
cies and on whether overall antibiotic use is reduced or
one antibiotic is simply replaced by another [81]. Models
that assume that ABR is not reversible effectively model
antibiotic effectiveness as a non-renewable resource [3,
78]; these models aim to find strategies that obtain the
greatest value from antibiotics before their effectiveness in
exhausted.
Discussion
Current evidence base
While the number of studies that estimate the cost of
ABR is rapidly accumulating, the majority of published
studies still ignore several biases and have too narrow a
focus to estimate the true cost of ABR. For example, we
found no studies that adjusted for time-dependent con-
founding using an appropriate methodology when esti-
mating the costs attributable to hospital-onset resistant
infections nor any studies that examined the impact that
future levels of ABR may have on clinical pathways.
Completely ignoring time-dependent confounding likely
leads to overestimation of the impact of ABR in the
hospital setting given that patients that develop an ABR
infection have likely deteriorated further between admis-
sion and acquisition than patients who remain infection
free [23]. Attempting to correct for time-varying con-
founding using inappropriate methodology, such as
standard regression techniques or multi-state models,
may only partly remove the indirect effects of early in-
fection that are mediated through the considered con-
founders, and may also introduce collider-stratification
bias, which can lead to either an over- or underestima-
tion of the true effect [14, 23, 26].
Jit et al. BMC Medicine           (2020) 18:38 Page 10 of 14
We also found few studies capturing wider costs beyond
hospital treatment costs (such as productivity costs, out-
of-pocket expenses, opportunity costs of lost bed days and
inability to use antibiotics, and costs associated with the
value of avoiding suffering), and few studies in low- and
middle-income settings. Consequently, it is likely that
most studies have overestimated current ABR costs in the
hospital setting (because of incomplete control for biases
and confounding) but underestimated total ABR costs (be-
cause of failure to account for wider societal costs and fu-
ture consequences of ABR).
Lastly, we found a variety of approaches to costing, in
line with previous reviews that concluded that heterogene-
ities in the quality of applied methods in ABR cost studies
prevented meaningful comparisons [11, 14, 16–18].
Conceptual framework
To address the limitations of existing studies, we have
developed a conceptual framework to highlight the ideal
scope and approaches for ABR cost estimations (Fig. 2).
We recognise that an analysis that is robust and compre-
hensive according to this framework likely cannot be
conducted at this time due to limitations in both data
and analytical methods. Hence, our framework points to
the need for better primary studies and surveillance to
inform the development of more methodologically ro-
bust models of ABR costs. In Table 2, we outline some
recommendations for the field.
Limitations
The framework was informed by a narrative review of
approaches and limitations that studies have taken to
costing ABR. A narrative review aims to interpret and
critique a large body of literature on a broad question,
rather than summarise or synthesise literature on a nar-
rowly focused topic [82]. In this case, it was appropriate
because the question we are addressing is wide ranging,
approaches to it are still being developed and the litera-
ture we reviewed is varied, including commentaries, pri-
mary data collection studies, economic evaluations and
conceptual models. The narrative review was informed
by a rapid literature search to obtain a broad overview of
the methods used by relevant papers, combined with a
review of references from previous reviews. The rapid
methodological review found 110 relevant studies, far
more than any other review of the topic in the literature.
Nevertheless, the review methodology we used was not
as exhaustive or unbiased as a full systematic review. In
particular, the search terms and range of databases we
searched were relatively limited because of the large
number of relevant articles.
Our conceptual framework builds on gaps identified in
current ABR estimates as well as on issues that have
been previously discussed or that were considered
important based on our own experience. Therefore, it is
not an exhaustive list of all issues that could be encoun-
tered when estimating the costs of ABR.
Conclusion
There is a clear need for more accurate estimates of the
current and future costs attributable to ABR to inform
decision-making around justified levels of investment in
interventions that address the challenge of increasing
ABR. Substantial improvements in methodological
Table 2 List of recommendations for future studies estimating
the cost of antibiotic resistance (ABR) and related interventions
Recommendations for primary data collection
• Capture all economic costs related to ABR in hospital patients, not
just the directly observed outcomes such as increased length of stay
• Explore use of g-methods to correct for both time-dependent biases
and time-dependent confounders in studies evaluating time-varying
exposures in hospital-based studies
• Exhaustively investigate potential confounders that need to be
collected and investigated in ABR cost studies, ideally using formal
causal inference methods such as causal diagrams
• Collect data on lost earnings and out-of-pocket expenses of patients
and caregivers so that the wider household and societal costs of
prolonged hospital stay and premature mortality can be captured;
this is especially important in settings with high out-of-pocket
medical expenses
• Consider reporting measures of the psychosocial burden of suffering
to patients and caregivers associated with illness, either by
monetising the value of avoided suffering or by reporting this
separately in units such as quality- or disability-adjusted life years
• Consider both quality (internal validity) and broader
representativeness (external validity) of data collected before
extrapolating from study sites to wider regions such as the national
or international level; if possible, data from multiple sites should be
synthesised using meta-analysis or meta-regression (including
geospatial variables, if appropriate)
• Implications of ABR outside the hospital setting should be
considered unless they are known to be negligible
Recommendations for further methodological development
• Investigate how levels of ABR may lead to increased costs for
everyone, including patients with susceptible infections, those
receiving antibiotics prophylactically and patients who are unable to
access hospital beds because they are occupied by patients whose
hospital stay has been extended by having a resistant infection
• Explore the use of longitudinal data from prospective cohorts or
large linked patient databases to understand the relationships
between antibiotic use, ABR and costs of ABR
• Ecological methods, such as regression, may allow extrapolation of
site- or region-specific costs to a national or global level, adjusting
for levels of ABR as well as other variables; however, further research
is needed to investigate the implications of model simplifications,
such as assuming linear and static relationships between antibiotic
use and ABR, and the use of alternative modelling methods
• Insights from transmission dynamic models of bacterial ecology and
from economic models of antibiotic market dynamics need to be
combined in order to inform optimal policies
• Explore ways that long-term projections and macro-economic
modelling can be incorporated into economic evaluations of
ABR-related interventions
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rigour and extension in time, perspective, scope and
space are needed to capture the true costs of ABR in fu-
ture studies. Furthermore, because better models cannot
overcome data limitations, investment in prospective
data collection is needed, including measurement of all
relevant potential (time-varying) confounders as well as
data on ABR infections and their associated costs and
health consequences. This is particularly true in low-
income settings where there is currently a clear lack of
reliable data. Such studies need careful a priori consider-
ation of potential confounders and biases. While this will
be no easy task, strengthening the robustness of evi-
dence on the true costs of ABR is critical to guide local,
national and global efforts to address the issue.
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